Camden Property Trust (CPT) is rated a buy due to improving fundamentals, prudent capital allocation, and a strong balance sheet. The company’s strategic repositioning in the Sun Belt region, including a $1.63 billion sale of California assets, is expected to boost long-term growth and capital flexibility. Positive trends in blended lease rates and rising occupancy support forecasted acceleration in funds from operations (FFO) growth through 2027 as supply pressures ease. CPT shares offer a 4.3% dividend yield and an attractive forward FFO yield of about 7%, with a price target of $115 based on a 6% FFO yield.
Camden Property Trust is the subject of this update. For readers following US real estate stocks, here is Pluang's market snapshot as of Sep 26, 2026 01:51 WIB: Among 26 priced real estate-sector US stocks, 8 rose and 18 fell. Notable movers include VICI Properties Inc at USD 23.41 with a 0.58% increase and 100% buy order activity, CubeSmart at USD 37.84 with a 0.56% increase, and EPR Properties at USD 56.50 with a 0.55% decrease and 100% buy order activity.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
